Document Detail


Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
MedLine Citation:
PMID:  7775629     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Combined hormonal oral contraceptives (OCs) may lead to a mild rise in blood pressure and body weight. In rare instances, large increments in blood pressure are measured. We investigated the effect of a combination of ethinyl estradiol (EE) plus a progestogen with antimineralocorticoid, i.e. natriuretic, properties [Drospirenone (DRSP)] on body weight, blood pressure, the renin-aldosterone system, atrial natriuretic factor, plasma lipids, and glucose tolerance. It is anticipated that this will lead to the development of an OC that does not raise body weight or blood pressure. Four groups of 20 women each received 30 micrograms EE plus 3 mg DRSP (group A), 20 micrograms EE plus 3 mg DRSP (group B), 15 micrograms EE plus 3 mg DRSP (group C), and, as a control OC, 30 micrograms EE plus 150 micrograms levonorgestrel (Microgynon, Schering; group D) for 6 months. During the OC-free control cycles before and after treatment and throughout treatment, the target parameters were measured. Between the pretreatment cycle and the sixth treatment cycle, mean body weight fell by 0.8 to 1.7 kg in groups A, B, and C (P < 0.05 vs. D), whereas it rose by 0.7 kg in group D. Systolic and diastolic blood pressures fell by 1-4 mm Hg in groups A, B, and C (significant for A and C vs. D) and increased by 1-2 mm Hg in group D. Renin substrate rose equally in all groups (P < 0.05), whereas PRA and plasma aldosterone rose significantly only in the DRSP groups, presumably due to sodium loss. In the DRSP groups, high density lipoprotein cholesterol rose (P < 0.05), in contrast to group D. Low density lipoprotein cholesterol fell slightly (P > 0.05), whereas triglyceride levels showed a stronger increase in the DRSP groups (P < 0.05) than in group D. All groups attained good cycle control; group A had the best. Side-effects were minimal. To our knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure. It may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure.
The potential of a new oral contraceptive (OC) containing drospirenone (DRSP) to avert the moderate increases in body weight and blood pressure often associated with use of existing combined OCs was investigated in a study of four groups of 20 German women each. Group A received 30 mcg of ethinyl estradiol (EE) and 3 mg of DRSP, Group B was administered 20 mcg of EE and 3 mg of DRSP, Group C received 15 mcg of EE and 3 mg of DRSP, and Group D was given a standard OC containing 30 mcg of EE and 150 mcg of levonorgestrel. Between the pretreatment cycle and the last (sixth) treatment cycle, mean body weight fell by 0.8-1.7 kg in Groups A, B, and C, but rose by 0.7 kg in Group D. Systolic and diastolic blood pressures fell by 1-4 mm Hg in Groups A, B, and C and rose by 1-2 mm Hg in Group D. Renin substrate rose equally in all four groups, while plasma renin activity, plasma aldosterone, and high density lipoprotein cholesterol rose significantly only in the three DRSP groups and serum triglyceride levels were significantly higher in Group D than in the three DRSP groups. Glucose tolerance increases were similar in all four groups. Finally, all groups--but especially Group A--experienced good cycle control and there were no serious side effects. These findings suggest that a combined OC containing DRSP may be especially beneficial for women who have a tendency to gain weight or experience a rise in blood pressure while taking OCs.
Authors:
W Oelkers; J M Foidart; N Dombrovicz; A Welter; R Heithecker
Related Documents :
15481699 - Cardiovascular and respiratory status in mechanically ventilated asphyxiated term infan...
21991739 - The effects of tourniquet on intraocular pressure during knee surgery.
7775629 - Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, dr...
3815009 - Comparison of low-osmolar contrast media in paediatric cardiac angiography.
8280559 - Improvement of brain electrical activity during treatment of porcine malignant hyperthe...
3261819 - Experimental study on diaphragm fatigue during diaphragm pacing.
1935709 - Cardiotoxicity and hypertension in rats after oral lead exposure.
3680599 - Phenylpropanolamine: effects on subjective and cardiovascular variables at recommended ...
975489 - The effect of a new anti-allergic drug ici 74, 9i7, given by aerosol, on nasal stenosis...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  80     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1995 Jun 
Date Detail:
Created Date:  1995-07-07     Completed Date:  1995-07-07     Revised Date:  2006-05-18    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1816-21     Citation Subset:  AIM; IM; J    
Affiliation:
Division of Endocrinology, Klinikum Benjamin Franklin (Steglitz), Freie Universität, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aldosterone / blood
Androstenes / administration & dosage,  adverse effects,  pharmacology*
Angiotensin I / blood
Blood Pressure / drug effects*
Body Weight / drug effects
Contraceptives, Oral, Combined / adverse effects,  pharmacology*
Ethinyl Estradiol / administration & dosage,  adverse effects,  pharmacology
Female
Glucose Tolerance Test
Humans
Lipids / blood*
Mineralocorticoids / antagonists & inhibitors*
Renin / blood
Renin-Angiotensin System / drug effects*
Chemical
Reg. No./Substance:
0/Androstenes; 0/Contraceptives, Oral, Combined; 0/Lipids; 0/Mineralocorticoids; 52-39-1/Aldosterone; 57-63-6/Ethinyl Estradiol; 67392-87-4/drospirenone; 9041-90-1/Angiotensin I; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stimulation of intracellular calcium concentration by adenosine triphosphate and uridine 5'-triphosp...
Next Document:  17 beta-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endoth...